Cancer chemotherapy update - Liposomal doxorubicin and bortezomib for relapsed or refractory multiple myeloma

Matthew R. Rutledge, James Waddell, Dominic A. Solimando

Research output: Contribution to journalReview article

Original languageEnglish (US)
JournalHospital Pharmacy
Volume45
Issue number3
DOIs
StatePublished - Jun 7 2010

Fingerprint

Multiple Myeloma
Drug Therapy
Neoplasms
liposomal doxorubicin
Bortezomib

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmacology (medical)

Cite this

Cancer chemotherapy update - Liposomal doxorubicin and bortezomib for relapsed or refractory multiple myeloma. / Rutledge, Matthew R.; Waddell, James; Solimando, Dominic A.

In: Hospital Pharmacy, Vol. 45, No. 3, 07.06.2010.

Research output: Contribution to journalReview article

@article{778448bd47814fd8968289e35e818f14,
title = "Cancer chemotherapy update - Liposomal doxorubicin and bortezomib for relapsed or refractory multiple myeloma",
author = "Rutledge, {Matthew R.} and James Waddell and Solimando, {Dominic A.}",
year = "2010",
month = "6",
day = "7",
doi = "10.1310/hpj4503-201",
language = "English (US)",
volume = "45",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "3",

}

TY - JOUR

T1 - Cancer chemotherapy update - Liposomal doxorubicin and bortezomib for relapsed or refractory multiple myeloma

AU - Rutledge, Matthew R.

AU - Waddell, James

AU - Solimando, Dominic A.

PY - 2010/6/7

Y1 - 2010/6/7

UR - http://www.scopus.com/inward/record.url?scp=77952995974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952995974&partnerID=8YFLogxK

U2 - 10.1310/hpj4503-201

DO - 10.1310/hpj4503-201

M3 - Review article

AN - SCOPUS:77952995974

VL - 45

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 3

ER -